Clinical trial · Interventional
18F-FET PET/CT in the Management of Glioma
Prospective Investigation in the Utility of Multiparametric 18F-FET PET/CT in the Management of Glioma: Application of PET Radiomics
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
O-(2-\[18F\]-fluoroethyl)-L-tyrosine (FET) is a tracer for positron emission tomography (PET). The Response Assessment in Neuro-Oncology (RANO) working group has officially recommended 18F-FET PET in the management of patients with brain glioma. Recently, the utility of 18F-FET PET in the diagnosis of fresh and residual gliomas has been reported by several investigators. But clinical usefulness of radiomics parameters has not been explored thoroughly in glioma patients. 18F-FET PET has been widely used in clinical studies or routine service in Europe, America, Mainland China, or Japan. However, 18F-FET PET is still not available in Taiwan. In this context, the investigator propose this study to explore the role of multiparametric 18F-FET PET imaging for glioma in Taiwan, with the emphasis in radiomics analysis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FET PET/CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 18F-FET PET
- description
- The study participants receive the 18F-FET PET scan.
- interventionNames
- Device: 18F-FET PET/CT
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 3 years
- description
- Overall survival is measured from the date of diagnosis to the date of death, or censored at last follow-up date.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with primary or recurrent brain tumors confirmed by pathological examination or imaging studies. 2. The ability to provide written informed consent and receive the scheduled scan. Exclusion Criteria: 1. Woman with pregnancy or during lactation. 2. Unsuitable for PET scans, such as those with claustrophobia or inability to lie flat. 3. Unable to sign the informed consent form. 4. Patients with a second primary tumor.
References
Publications (1)
- DERIVEDChan SC, Chiu TL, Ng SH, Kao HW, Tsai ST, Liu SH. 18F-FET PET/CT can aid in diagnosing patients with indeterminate MRI findings for brain tumors: a prospective study. Ann Nucl Med. 2025 Apr;39(4):342-352. doi: 10.1007/s12149-024-02005-4. Epub 2024 Nov 26. PMID 39589672